BIOCRYST PHARMACEUTICALS INC
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
During the three months ended September 30, 2025, two of the directors and officers of the Company adopted, modified orterminated the “Rule 10b5-1 trading arrangements” (as such term is defined in Item 408(a) of Regulation S-K) as set forth in the table below.
| Name (Title) | Action | Date of Action | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|
| Alane P. Barnes,Chief Legal Officer and Secretary | Modification | August 13, 2025 | Until December 20, 2027, or such earlier date upon which all transactions are completed or the plan is terminated | (1) |
| A. Machelle Sanders, Member of the Board of Directors | Adoption | August 14, 2025 | Until December 31, 2025, or such earlier date upon which all transactions are completed or the plan is terminated | (2) |
(1) This trading plan was originally adopted on December 1, 2022 (the “2022 Barnes Plan”) and provided for the sale of up to (i) 24,710 shares of common stock and (ii) 137,897 shares of common stock underlying stock options through December 29, 2025. The 2022 Barnes Plan was amended on May 15, 2024 to cancel all open orders under the 2022 Barnes Plan and to provide for the sale of up to 119,897 shares of common stock underlying stock options expiring in 2024 and 2025 (the “2024 Barnes Plan”). The 2024 Barnes Plan was amended on August 13, 2025 (the “2025 Barnes Plan”) to cancel all open orders under the 2024 Barnes Plan and to provide for the sale of up to (i) 123,100 shares of common stock underlying restricted stock units, net of shares withheld to cover taxes, (ii) 19,770 shares of common stock, and (iii) 347,501 shares of common stock underlying stock options expiring in 2025 through 2027, pursuant to the terms of the 2025 Barnes Plan.
(2) This trading plan (the “Sanders Plan”) provides for the sale of up to 9,600 shares of common stock, pursuant to the terms of the Sanders Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.